PDE4B and systemic sclerosis: Therefore, BI 1015550, as a PDE4B inhibitor, may exert its therapeutic effect by increasing cAMP levels in silicosis, and the same mechanism of action of BI 1015550 has been confirmed in SSc-ILD.